Globus Medical (NYSE:GMED) Price Target Raised to $120.00

Globus Medical (NYSE:GMED) had its price target increased by Royal Bank Of Canada from $115.00 to $120.00 in a research report released on Friday,Benzinga reports. They currently have an outperform rating on the medical device company’s stock.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Canaccord Genuity Group boosted their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Piper Sandler reissued an “overweight” rating and issued a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research note on Thursday, January 8th. Barclays lifted their price target on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Truist Financial set a $115.00 price target on shares of Globus Medical in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Stock Down 0.2%

Shares of NYSE:GMED opened at $77.81 on Friday. The company has a market capitalization of $10.52 billion, a price-to-earnings ratio of 18.10, a price-to-earnings-growth ratio of 1.71 and a beta of 1.00. Globus Medical has a 52 week low of $51.79 and a 52 week high of $101.40. The firm has a 50 day moving average of $89.86 and a 200 day moving average of $86.65.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts expect that Globus Medical will post 4.74 EPS for the current year.

Insider Transactions at Globus Medical

In other Globus Medical news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Institutional investors and hedge funds have recently bought and sold shares of the company. SBI Securities Co. Ltd. grew its holdings in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Globus Medical during the third quarter valued at $26,000. EverSource Wealth Advisors LLC grew its holdings in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Globus Medical by 83.4% during the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after buying an additional 242 shares during the last quarter. Finally, First Horizon Corp purchased a new stake in shares of Globus Medical during the third quarter valued at $31,000. 95.16% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title
• Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title
• Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title
• Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.